Treatment of Esophageal Cancer with Cervical Lymph Node Metastasis

Initial Staging and Classification

For upper thoracic esophageal tumors, cervical lymph node metastases are classified as M1a disease and considered regional spread within the esophageal drainage area, according to the American Joint Committee on Cancer 1, 2, 3
For mid-thoracic tumors, cervical nodes are NOT considered regional, as stated by the National Comprehensive Cancer Network 1, 2
For lower thoracic tumors, cervical lymph nodes represent M1b distant metastases, as defined by the American Joint Committee on Cancer 1, 2, 3

Definitive chemoradiation is the standard treatment for upper thoracic squamous cell carcinoma with cervical nodes, with surgery reserved only for highly selected patients who achieve excellent response, as recommended by the National Comprehensive Cancer Network 1, 2, 4
The primary treatment approach for upper thoracic squamous cell carcinoma includes cisplatin/5-FU combined with 40-50 Gy radiation, as suggested by the European Society for Medical Oncology 5, 6, 7
Close surveillance during treatment with endoscopy and CT imaging is necessary for upper thoracic squamous cell carcinoma, as recommended by the American Society of Clinical Oncology 1, 2

For patients not candidates for curative-intent therapy, palliative treatment focuses on symptom management, including single-dose brachytherapy for dysphagia, as recommended by the American Society for Radiation Oncology 1, 2, 4
Palliative chemotherapy is indicated for selected patients with good performance status, as suggested by the European Society for Medical Oncology 1, 2, 4

Primary interdisciplinary treatment planning is mandatory before initiating any therapy, including medical oncology, radiation oncology, thoracic surgery, gastroenterology, and nutrition support, as recommended by the National Comprehensive Cancer Network 1, 2, 5, 6

The European Society for Medical Oncology recommends combining cisplatin/5-FU chemotherapy with 45-50 Gy external beam radiation therapy (EBRT), followed by brachytherapy boost, as the optimal regimen for squamous cell carcinoma of the upper thoracic esophagus 8

Brachytherapy should not be used in patients with tracheal or bronchial involvement, cervical esophagus location, stenosis that cannot be bypassed with the applicator, or prior endobronchial radiation in the same area within 6 months, according to the European Respiratory Society 9, 10

Brachytherapy provides long-term palliation in 50% of patients and improves hemoptysis in >90% of cases, as reported by the European Respiratory Society 9, 10

Fatal hemorrhage is a potential late complication, occurring in 7-15% of patients, as reported in the journal Chest 11
Tracheoesophageal fistula, soft tissue necrosis, radiation bronchitis, and stenosis are also potential late complications, according to the European Respiratory Society 9, 10

Single-dose brachytherapy provides better long-term relief of dysphagia with fewer complications than metal stent placement in patients with metastatic disease or poor prognosis, as reported in the journal Gut 12, 8

Stent placement before multidisciplinary review leads to higher morbidity, mortality, and lower R0 resection rates, as reported in the journal Clinical Gastroenterology and Hepatology 13
Inadequate dose delivery, with doses below the recommended levels, may compromise local control, and proper applicator positioning is crucial to avoid late complications, according to the European Respiratory Society 9, 10